With this patent now in place, MYOS has an even clearer runway as a wholly-unique, all-natural, clinically proven supplement in the rapidly-growing and increasingly competitive animal health industry.
“MYOS stands out in protecting our innovative products with patents backed by clinically-validated, peer-reviewed studies,” said MYOS CORP CEO Joe Mannello. “We’re gratified that the US Patent Office continues to recognize the distinctiveness and effectiveness of Fortetropin, granting us robust patent protection.”
While numerous pet supplement brands claim an ability to enhance joint health as a way to combat the symptoms of aging, MYOS stands alone as the only company to offer a unique, clinically proven product to address muscle health. With eight published clinical studies and now eight U.S. patents, MYOS continues to build an impressive IP Portfolio that acts as a powerful separator from its competitors.
The global pet supplement market is experiencing rapid growth, reflecting a broader trend in pet care toward health and longevity. This expansion is particularly pronounced in the realm of senior dog care, where a growing number of products are being developed and marketed specifically for aging canines. This segment’s growth is fueled by pet owners’ increasing willingness to invest in their pets’ health, akin to how they care for human family members.
About MYOS CORP
MYOS CORP is a Cedar Knolls, NJ based medical nutrition company that develops products that improve muscle health in people and animals. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size, lean body mass, and reduce muscle atrophy. MYOS products include MYOS Canine Muscle Formula®, MYOS Feline Muscle Formula®, MYOS Equine Muscle Formula®, and YOLKED®. For more information, please visit www.myoscorp.com. If you have any questions please contact [email protected].
For example, Native American communities face double the risk of diabetes; African American communities exhibit a 77% higher diabetes risk; and Latino and Hispanic communities confront a 66% elevated diabetes risk, a 48% increased amputation rate and a 50% higher risk of diabetes-related mortality.
Lavior was founded by Gilad and Anabelle Savion, who have built a comprehensive R&D team to study the radical healing effects of the Inula AGS-RIED species used in the creams.
“As experts in rapid-healing diabetic wound care, we offer a practical solution for at-home diabetic care,” said Gilad. “We invested time and extensive research, backed by 13 years of studies in natural treatment for skin disorders, to develop creams to help the millions of people affected by this all-too-common disease. Together with the ADA and Walmart, we will continue to shed light on the importance of early detection and care for all communities. Diabetes affects all ages and that is why we must continue to educate ourselves on the risks and treatments readily available to improve quality of life.”
Lavior’s groundbreaking formulations and medical understanding of chronic skin disorders have resulted in breakthrough findings for diabetic skin conditions. Essential for any first aid kit, the all-in-one Lavior creams feature an advanced formula that provides moist wound healing through its unique ability to address multiple wound concerns simultaneously. Its therapeutic properties protect wounds while soothing and hydrating dry, cracked and damaged skin and healing diabetic wounds and foot ulcers.
About Lavior: Lavior is the only company exclusively dedicated to the therapeutic diabetes skincare market. The Lavior skincare product line soothes and heals some of the most widespread and challenging skin problems – diabetic ulcers, wounds, burns, eczema/atopic dermatitis, bacterial and fungal infections, skin irritations and cracked skin. Lavior’s line of products is based on the proven efficacy of the Inula AGS-RIED botanical species. They are developed using the highest quality, pharmaceutical-grade ingredients, manufactured and tested to deliver safe, effective and compliant products. Backed by over 13 years of extensive research and clinical trials, proven clinical safety and efficacy, they consistently outperform conventional treatments.
The most active companies forming deals and collaborations in cell and gene therapy across a variety of categories include:
Oxford BioMedica
Astellas Pharma
Takeda Pharmaceutical
Eli Lilly
Bristol Myers Squibb
Novartis
Ginkgo Bioworks
Cytiva (Danaher)
Resilience
Fujifilm
Cell and gene therapy presents promising treatment avenues for various acquired illnesses like cancer, diabetes, Parkinson’s disease, and genetic disorders by addressing faulty genetic material. A recent example of the industry’s newsworthy relevance came on December 8, 2023, when the US Food and Drug Administration (FDA) approved two gene therapies for sickle cell in a move that offers hope to thousands of people living with the debilitating and life-shortening inherited red blood cell disorder. The FDA’s approval also carries a historic distinction because one of the new therapies is the first commercially available treatment based on gene-editing technology in the United States.
Overall, the cell and gene market is also seeing these therapies extending their reach into diverse medical domains. This encompasses autoimmune diseases, cardiovascular conditions, musculoskeletal disorders, dermatological ailments, and various other areas.
As the industry advances, cell and gene therapy-related companies have continued to receive huge investments, though the annual total amounts have dipped year-to-year since 2021. The tighter funding environment is not unique to cell and gene therapy and has been seen across other industries. IPOs/FPOs dropped significantly but recovered to an extent. In practical terms, because cell and gene therapy companies are mostly startups, this tighter funding has been experienced as a lower average funding round for VC/private funding, while the number of those deals has remained consistent.
M&A activity, despite accounting for the most funding, has been extremely inconsistent. In the meantime, the number of certain categories such as collaborative deals, licensing, manufacturing/supply chain, and distribution/co-marketing agreements, have been mostly rising at varying rates. Collaboration payments have been a much lower dollar amount, but with large potential milestone payments; the payments being made are fairly consistent in the range of $500 million to $1 billion total per quarter. Those patterns seem to indicate a growing and maturing industry as a whole, despite the varying levels of funding.
About the Report
This Kalorama Information report is designed to provide companies entering or already in this market with knowledge of the trends in deals that will shape future growth and competition.
The report tracks the dealmaking activities in cell and gene therapy since 2021. The report provides informative graphs of quarterly trends from 2021-2023 and also includes the specific details of over 2,000 deals covering the Q1 2022-Q3 2023 period. A lot of attention and funding is being given to the areas related to cell and gene therapy (CGT) recently. Kalorama’s tracked CGT investments, acquisitions, and other deals amounted to tens of billions of dollars in the first three quarters of 2023. Understanding the volumes of deals that have been made, who is making which type and how many, and the deals’ details, is critical to finding how to take advantage of the opportunities in one of the fastest-growing markets.
Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals. Kalorama Information produces dozens of reports a year. The firm offers a Knowledge Center, which provides access to all published reports.
Kalorama Information’s studies feature independent primary research conducted by experienced analysts. Researchers build their market analysis independently from published databases, validating data with inside industry contacts and extensive secondary research, so you can have confidence that you’re getting your information from the most trusted source in the industry!
The Gallery redefines senior living with amenities extending beyond the essentials, featuring a two-story grand hall with a lavish fireplace, a grand piano designed by a local artist and provides a diverse range of spaces for socializing and relaxation including a pub, rooftop garden, private family dining, multiple courtyards, a library, community room, salon, and theater. For Memory Care residents, a dedicated courtyard and activities area ensures a tailored experiences for all residents.
“I’m thrilled to have our newest community opening so close to my own home, in a neighborhood I cherish”, commented ESL President Phill Barklow. “The Gallery at Ft. Collins will be a vibrant senior living community that will seamlessly blend art and music with the rich culture of the Fort Collins community, providing the perfect backdrop for our residents to enjoy life.”
Nuveen Real Estate and Brinkmann Constructors will also partner with ESL on the project.
“The Gallery at Ft. Collins aligns with Nuveen’s thesis of developing new, state-of-the-art senior living communities for the next generation of seniors in high-barrier-to-entry markets like Fort Collins“, noted Andrew Pyke, Head of Healthcare Real Estate at Nuveen. “We are excited to partner with a first-class operator like ESL to bring this project to the Fort Collins community.”
For more information on Experience Senior Living communities, visit our website at www.experiencesrliving.com.
About Experience Senior Living
Experience Senior Living is a full-service, vertically integrated owner, developer and operator of active adult, independent living, assisted living, and memory care communities. We are reimagining senior housing by leveraging our vast experience to seamlessly integrate strategic, operational and human-centered aspirations. We translate those experiences to create new and inspiring models of care focused on hospitality, which are responsive to residents’ needs and centered around holistic wellness and engagement with a broader community. Experience drives everything we do, and our team of dynamic professionals is fueled by their passion for empowering individuals to lead enriching lives at every stage of their journey. Experience Senior Living is based in Denver, with communities operating or under development in seven states: Colorado, Florida, Indiana, Maryland, Ohio, Virginia, and Washington.
The relationship with Twin Brook gives Med First the access to debt capital to continue to execute on its growth plan through de novo and acquisitions to enhance and expand its geographic footprint served.
Chris Rogers, Senior Managing Director in Ziegler’s Healthcare Corporate Finance practice, commented, “We were thrilled to partner with the team at Med First and Sverica to support the Company on an inflection point in its growth journey. Med First’s innovative operating model and proven clinic expansion infrastructure and playbook, coupled with Twin Brook’s expertise in the healthcare services sector, will allow Med First to capitalize on the opportunity to expand its breadth of services and patients reached across the Southeast and Atlantic Coast regions. We are excited to see Med First continue to broaden its reach and ability to engage with the underserved communities through this new partnership.”
Ziegler’s Healthcare Investment Banking team is focused on delivering best-in-class advisory and financing solutions for companies and organizations across the healthcare industry. In our core practice areas of healthcare services, information technology, hospitals and senior living, Ziegler is one of the most active M&A firms offering innovative sell-side, buy-side, recapitalization/restructuring, equity private placement and strategic partnering services.
About Ziegler: Ziegler is a privately held, national boutique investment bank, capital markets and proprietary investments firm. It has a unique focus on healthcare, senior living and education sectors, as well as general municipal and structured finance. Headquartered in Chicago with regional and branch offices throughout the U.S., Ziegler provides its clients with capital raising, strategic advisory services, fixed income sales, underwriting and trading as well as Ziegler Credit, Surveillance and Analytics. To learn more, visit http://www.ziegler.com.
Certain comments in this news release represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. This client’s experience may not be representative of the experience of other clients, nor is it indicative of future performance or success. The forward-looking statements are subject to a number of risks and uncertainties, in particular, the overall financial health of the securities industry, the strength of the healthcare sector of the U.S. economy and the municipal securities marketplace, the ability of the Company to underwrite and distribute securities, the market value of mutual fund portfolios and separate account portfolios advised by the Company, the volume of sales by its retail brokers, the outcome of pending litigation, and the ability to attract and retain qualified employees.
“We are fortunate to have a growing library of rare and valuable biospecimens that have contributed to the fight against cancer in PLWH,” said Dr. Paige Bracci, UCSF Professor of Epidemiology and Biostatistics, and Director of the ACSR’s Informatics program. “Concentriq for Research has enabled us to quickly realize the benefits of digital pathology and get this real-world data in the hands of more researchers faster. Proscia’s platform is not only making a difference for the scientific community but also for the patients impacted by its work.”
Since selecting Concentriq for Research, the ACSR has reduced the time it takes to provide investigators with pathology data from days to hours. As the enterprise pathology platform facilitates the sharing of images instead of glass slides, the ACSR can transcend geographical barriers and simultaneously share the same datasets so that more research teams can drive scientific advancements. In addition, this approach allows for conservation and increased sustainability of rare and exhaustible tissue specimens to a large number of individual researchers. Concentriq for Research also offers robust annotation and analysis tools to empower investigators in their work.
“We are proud to count the ACSR among the members of the Concentriq community,” said David West, Proscia’s CEO. “It enables breakthrough research with its pathology data and has meaningfully improved access to this critical source of insight with our platform. We look forward to seeing the impact that the ACSR continues to make with enterprise digital pathology.”
Along with today’s news, the ACSR has announced the availability of a rare melanoma tissue repository on Concentriq for Research. A corresponding tissue microarray of these tumor tissues will be available in early 2024.
About The AIDS and Cancer Specimen Resource
The AIDS and Cancer Specimen Resource (ACSR) biorepository includes specimens collected from PLWH who have been diagnosed with a wide spectrum of conditions and diseases, particularly cancers, pre and post-HAART. The ACSR’s mission is to acquire, store, and equitably distribute these tissues and biological fluids along with associated clinical data to investigators conducting HIV related research. For more information, visit acsr1.com.
About Proscia
Proscia is a software company accelerating the transformation to digital pathology to change the way we understand diseases like cancer. Its Concentriq enterprise pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate R&D, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies rely on Proscia’s software each day. For more information, visit proscia.com.
Disclaimer: NIH does not endorse or recommend any commercial products, processes, or services. The views and opinions do not necessarily state or reflect those of the U.S. Government.
The IVDR also introduces changes in the classification and risk assessment of in vitro diagnostic devices. Manufacturers must meticulously assess the risk profile of their products, which may lead to reclassification and the need to modify device labeling and documentation accordingly. These demands have increased the compliance burden, demanding a significant investment of time and resources.
The IVDR also champions transparency. Manufacturers are required to furnish comprehensive information on device performance, clinical evidence and instructions for use. This enhanced transparency equips users with richer data, enabling more informed decision-making in clinical practice. Moreover, the regulation emphasizes post-market surveillance and reporting, which should lead to improved data quality. This is anticipated to raise the overall quality of diagnostics, ultimately resulting in improved patient care.
Join this webinar to learn how the new In Vitro Diagnostic Regulation (IVDR) impacts manufacturers and users of diagnostic devices.
Join experts from Cerba Xpert, Dr. Sébastien Barradeau, Global Head of IVD Medical Device; and Marie-Laure Delalande, Head of IVD Operations, for the live webinar on Tuesday, January 9, 2024, at 10am EST (4pm CET/EU-Central).
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Without globally inclusive patient registries, advancements in research and development of cures for rare diseases become less equitable and accessible. “What we need are registries focused on a given disease globally, not biased by a regional population, so as to benefit all patients,” he says. Creation of well-designed patient registries that include highly populous countries like India provide the data needed to compile a complete understanding of the natural history of a disease, accelerating the global advancement of the development of treatment efforts. The current system is inefficient and misses the reality of the differences in how patients in low-and-middle-income-countries (LMICs) such as India might experience a disease versus how patients in the western world do, due to variability in genetics, infrastructure, environmental, and lifestyle factors. Patient registries have also proven to be valuable databases for accelerating patient recruitment for clinical trials.
Rajasimha explains how Jeeva provides a user-friendly and affordable platform to create high-quality patient registries that empower researchers to better understand the disease heterogeneity and natural history in the general population and the need to expand beyond the Caucasian population.
In October 2023, Dr. Rajasimha chaired the Indo U.S. Bridging RARE Summit 2023, which shone a spotlight on the recent gene therapies approved by the FDA. Dr. Peter Marks’s keynote address at the conference highlighted the need for global collaboration and cooperation on the creation of patient registries, clinical trials, and orphan drug launches, including in countries like India, to combat the currently biased datasets and to ensure the benefits of gene therapy advances are accessible and affordable. For instance, a global registry of all people affected by sickle cell disease could be more effective than having regionally siloed registries.
The recent launch of the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program could be a game changer. The idea is to treat each rare disease as a global public health emergency and make “operation warp speed” a reality on an ongoing basis at affordable costs. It is open to sponsors of products currently in clinical trials under an active Investigational New Drug application (IND). START’s goal is to provide advice and regular ad-hoc communication with FDA staff to address product-specific development issues, including, but not limited to, clinical study design, control group choice, and fine-tuning the patient population.
Successful outcomes with gene therapies
More and more, gene therapies are offering improved outcomes for diseases. A new study by the Tufts Medical Center’s New Drug Development Paradigms (NEWDIGS) program, funded by the Alliance for Regenerative Medicine, found that durable cell and gene therapies for blood cancers and orphan diseases are 2 to 3.5 times as likely to succeed than other therapeutic modalities for similar conditions.(3)
Profound genetic hearing loss due to mutations of the otoferlin gene has had positive results using gene therapy in two separate trials. While this mutation is rare, causing only 1 to 3% of cases of hearing loss, the successful trial represents a crucial step forward, as there are currently no treatments for hearing loss except cochlear implants.(4)
As of November 21, 2023, more than 5,900 clinical trials are underway focused on some form of gene therapy.(5) The number of people worldwide living with a rare disease is estimated to be 300 million, affecting at any point in time somewhere between 3.5 to 5.9% of the population.(6)
Make treatments global
These advances are exciting, but global treatment availability is necessary for all patients to benefit. The enactment of The Orphan Drug Act (ODA) of the US FDA in 1983 has aided the approvals of about 1100 orphan drugs, as it provided financial incentives for companies to focus on combating these rare conditions.
However, as we celebrate the 40th anniversary of ODA, Rajasimha explains, all stakeholders recognize that the patients in these trials have not been representative of the global population, as most of the trial participants have been limited to the U.S. and the European Union. A biased data set leads to biased treatment development, leaving out almost 90% of the world’s population from receiving the same treatment benefit.
Additionally, advances in artificial intelligence and machine learning present an opportunity to expand patient registry data. Still, AI and machine learning models are likely being trained based on the available biased datasets, meaning that insights gained from these advances in AI and ML are limited and unlikely to benefit most global citizens.
Registries form the foundation for addressing health economic and other inequities
Regarding treatments for rare diseases, economics is still hindering greater advancements in science and medicine. Questions remain about the ability of patients to afford treatments and whether governments will be able to negotiate with the regulatory review and approval process to increase access.
Rajasimha stresses how relying on regional patient registries does not permit economies of scale that allow biotech companies to progress on their gene therapies pipelines. “Small and emerging biotech companies that are investing in research and development of gene therapies for rare diseases may find it impossible to recover the cost of R&D by recruiting from regional registries alone that may only have a few hundred patients,” he explains. But with global registries, that number could grow to thousands for a particular disease, creating a much greater opportunity to understand the disease epidemiology and heterogeneity, including most patients, and to allow biotech companies to recoup their expenses post approval by the regulators.
Engaging the rest of the world (regions beyond the U.S. and E.U.) in patient registries and orphan drug development is essential to overcome the challenges of DEIA in rare diseases research. These are critical success factors that impact the downstream recruitment of patients for clinical trials and the eventual commercialization of successful drugs.
Jeeva’s eClinical Cloud is a versatile unified platform for creating global patient registries. It has recently launched an emerging markets program to help address these massive inequities and access challenges to help engage low-and-middle-income countries (LMICs) to participate in the rare disease revolution. The platform allows researchers to engage researchers and patients remotely, collect data in real-time and achieve patient retention during long-term follow-ups, a crucial issue for many clinical trials.
Jeeva’s modular platform includes electronic data capture (EDC) module compliant with the FDA 21 CFR part 11 and other regulatory guidelines yet affordable for nonprofit patient organizations and public health institutions. EDC is a software used for collecting clinical trial data via electronic (usually web-based) case report forms (eCRFs) and questionnaires for gathering information about a study participant. The primary goal of this platform is to ensure that researching rare disease solutions becomes more productive for biotech companies in emerging markets. It is vital for regulatory bodies such as the FDA accept this clinical trial data from these other countries, an issue that the START program is working to address.
Rajasimha was a speaker on these topics at the Society for Clinical Data Management India conference on December 1st in Bengaluru and the Indian Academy of Medical Geneticists (IAMG) conference on December 2nd in New Delhi.
Rajasimha concludes, “We need to go global because we don’t have quality clinical data in the rest of the world like we do in the U.S. and Europe. During my two decades of research experience, it has perplexed me that biomedical science is data-driven, yet very little attention goes towards ensuring that the data is inclusive and representative of all humans. It’s incomplete and biased science. We really need to help the creation of national, international, and global patient registries including in countries such as India and the rest of the world, for all rare and neglected diseases. It is a prerequisite to accelerating the research and development of treatments of rare diseases that can be affordable, accessible and beneficial to all people.”
About Jeeva Informatics Solutions The personal experience of losing a child born with a rare congenital disorder and a brother with a chronic disease became the springboard for Dr. Harsha Rajasimha to apply his years of postdoctoral research experience at the NIH and FDA to accelerate therapies for rare and common conditions. He founded Jeeva with the mission of lowering the cost of drug development and accelerating the speed of clinical trials by purpose-building a modern technology platform that empowers sponsors to run clinical trials, with fewer fragmented systems, fewer employees, with significantly less burden on clinical researchers and patients, which has allowed for a more globally diverse population to access clinical trials remotely.
Today the Jeeva eClinical Trial platform supports sponsors and CROs across the globe helping reduce the logistical burdens on patients and study teams by over 70%. Its complete suite of technology supports fully decentralized and hybrid clinical trials and has resulted in being selected by research hospitals, CROs, and sponsors developing pioneering therapeutics such as Frantz Viral Therapeutics and ImmunoACT. The Virginia-based company’s modular cloud-resident software-as-a-service is highly scalable and facilitates patient enrollment, engagement, and evidence generation in clinical trials from one login from any browser-enabled mobile device. Visit https://jeevatrials.com/
References 1) Eglovitch, Joanne S.; “Convergence: CBER chief discusses priorities, touts gene therapy approvals”; Regulatory Focus; 5 October 2023; raps.org/News-and-Articles/News-Articles/2023/10/Convergence-CBER-chief-discusses-priorities,-touts. 2) “Cell and Gene Therapy Manufacturing Costs Limiting Access”; Genetic Engineering & Biotech News; 21 February 2023; genengnews.com/insights/cell-and-gene-therapy-manufacturing-costs-limiting-access/. 3) Pratap, Aayushi; “Study Highlights Standout Clinical Success of Certain Cell and Gene Therapies”; BioSpace; 6 November 2023; biospace.com/article/study-highlights-superior-clinical-success-of-certain-cell-and-gene-therapies-/. 4) “Gene Therapy Racks up Success in Rare Genetic Hearing Disorder”; Inside Precision Medicine; 30 October 2023; insideprecisionmedicine.com/topics/patient-care/gene-therapy-racks-up-success-in-rare-genetic-hearing-disorder/. 5) Clinical Trials; Accessed 21 November 2023; classic.clinicaltrials.gov/ct2/results?recrs=&cond=&term=gene+therapy&cntry=&state=&city=&dist=. 6) “New scientific paper confirms 300 million people living with a rare disease worldwide”; Rare Disease International; 15 October 2019; rarediseasesinternational.org/new-scientific-paper-confirms-300-million-people-living-with-a-rare-disease-worldwide/.
Media Contact
Karla Jo Helms, JOTO PR™, 727-777-4629, [email protected], jotopr.com
Briefly, prior to hybrid capture, the corresponding single-cell genomic libraries were subjected to low-coverage WGS (lcWGS) to ascertain copy number alterations, revealing ductal carcinoma in situ/ infiltrating ductal carcinoma of the breast (DCIS/IDC)-prototypical and heterogeneous chromosomal lesions. Full-transcript RNA-seq data and BioLegend antibody-based surface protein targets were jointly assessed from the transcriptomic libraries of ResolveOME, enabling cell type identification and phenotypic cell state inference. The data indicates the successful merging of the ResolveOME multiomic workflow with a single-cell exome survey, enabling analysis of copy number variants (CNV) in the context of a complete transcriptome with a focal targeted protein assessment.
Join this webinar to explore a new method detailing genetic insights into breast cancer, enabling precise assessment of variations, gene expressions and targeted proteins at a single-cell level.
Join Katie Kennedy, PhD, ASCP (MB), Manager Services Department, BioSkryb Genomics, for the live webinar on Monday, December 18, 2023, at 2 pm EST (11 am PST).
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
“We are thrilled to welcome WellPha into the Synergy family,” said Jennifer Arms, managing partner for Synergy Billing Corp. “WellPha’s needs are specific, as with many specialty pharmacies. We understand this because each of our customers has touchpoints that require a revenue cycle partner that prioritizes customization while also bringing industry familiarity to the process.” Arms continued, “We believe in this partnership and look forward to seeing it continue to grow in years to come.”
Bernard Fischman, co-owner of WellPha, shared his support for the partnership: “Choosing Synergy Billing Corp was a strategic decision. The complexities of billing for Medicare hemophilia patients require precision and familiarity. Synergy’s experience in this niche and its commitment to tailored solutions assured us they could help us effectively navigate the process. This partnership enhances our operational efficiencies and enables us to extend our services to an even broader patient population.”
Synergy takes pride in tailoring its revenue cycle management services to meet each customer’s unique needs, ensuring that no two service profiles are identical. This high-touch approach has driven the company’s growth in a successful first half of 2023, with Synergy reporting:
An 82% increase in revenue over the same period in 2022
Earnings grew by 1,021% compared to the same period last year
A 36% increase in the number of clients from this time a year ago
Fifteen (15) new employees have been onboarded
Synergy Billing Corp. is committed to setting the industry standard for every customer. Visit www.synergybillingcorp.com to learn more, or call us at 412.909.4064.
About Synergy Billing Corp.
Synergy Billing Corp. is a boutique firm that provides revenue cycle and consulting solutions to home infusion and specialty pharmacy healthcare companies. Synergy specializes in assisting with home infusion reimbursement and removing administrative burdens, allowing clients to stay focused on their primary business. The company supports its clients through all phases of the revenue cycle, including benefits verification, pre- and continuing authorizations, billing, collections, and cash posting. Synergy Billing Corp. was founded in 2018 and is headquartered in High Point, N.C. For more information, visit www.SynergyBillingCorp.com or connect with us on LinkedIn or Instagram.
About WellPha Specialty Pharmacy
WellPha Specialty Pharmacy delivers highly customized, home-based infusion and specialty medical treatment services to patients nationwide. The company, founded in 2021 and headquartered in Brooklyn, NY, offers premium pharmaceutical products and leading customer service that elevates the patient, provider, and manufacturer experience. WellPha’s singular mission is to ensure the best treatments for each condition, centered on its promise of care, compassion, and expertise with every interaction. For a complete listing of available therapeutics and disease management services or to learn more about WellPha Specialty Pharmacy, visit www.WellPha.com.
